(P-102) Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

NM

Nichole McGhee, B.S.

Moderna, Inc.
Cambridge, Massachusetts, United States
SC

Spyros Chalkias, MD (he/him/his)

Senior Medical Director
Moderna, Inc.
Cambridge, MA, United States
JW

Jordan L. Whatley, MD

Meridian Clinical Research
Baton Rouge, Louisiana, United States
Brandon Essink, M.D.

Principal Investigator
Meridian Clinical Research
Omaha, Nebraska, United States
AB

Adam Brosz, M.D.

Meridian Clinical Research
Grand Island, Nebraska, United States
BG

Bethany Girard, PhD

Moderna, Inc
Cambridge, Massachusetts, United States
DW

Darby Wang, BS

Moderna, Inc
Cambridge, Massachusetts, United States
Ed

Elizabeth de Windt, MPH

Moderna, Inc.
Cambridge, Massachusetts, United States
DE

Darin Edwards, Ph.D.

Moderna, Inc.
Cambridge, Massachusetts, United States
JF

Jing Feng, M.S.

Moderna, Inc.
Cambridge, Massachusetts, United States
AS

Angeline Sanders, MS

PPD, part of Thermo Fisher Scientific
Wilmington, North Carolina, United States
DM

David C. Montefiori, PhD

Duke University Medical Center
Durham, North Carolina, United States
JM

Jacqueline Miller, MD

Moderna, Inc.
Cambridge, Massachusetts, United States
RD

Rituparna Das, M.D.

Moderna, Inc.
Cambridge, Massachusetts, United States